Keywords: Mantle cell lymphoma; Geriatric assessment; Chemotherapy; Ibrutinib; Rituximab; Bendamustine; Lymphoma;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Bendamustine; CLL; Ibrutinib; Idelalisib; Obinutuzumab; Venetoclax;
Keywords: Aggressive lymphoma; Bendamustine; Diffuse large B-cell lymphoma; Immunochemotherapy; Indolent lymphoma;
Keywords: BEN; bendamustine; CI; combination index; CLB; chlorambucil; CLL; chronic lymphocytic leukemia; Cyclo; cyclophosphamide; dADO; deoxyadenosine; Del; deletion; DHE; dihydroethidium; DiOC6; 3,3â²-dihexyloxacarbocyanine iodide; DMSO; dimethyl sulfoxide; DR;
Keywords: bendamustine; chronic lymphocytic leukemia; economic evaluation; obinutuzumab; ofatumumab; rituximab;
Keywords: Bendamustine; Brentuximab vedotin; Hodgkin's lymphoma; Refractory; Relapsed
Keywords: Mantle cell lymphoma; Relapsed/refractory; Bendamustine; Bortezomib; Ibrutinib; Autologous hematopoietic cell transplant; Allogeneic hematopoietic cell transplantation;
Keywords: Bendamustine; BR; Chemoimmunotherapy; CLL; FCR
Alkylating Agents in the Treatment of Waldenström Macroglobulinemia
Keywords: Alkylating agents; Waldenström macroglobulinemia; DRC; CHOP; Bendamustine;
What is the optimal initial management of the older MCL patient?
Keywords: Mantle cell lymphoma; Elderly patients; Induction therapy; Maintenance therapy; R-CHOP; Bendamustine; Cytarabine; Lenalidomide; Bortezomib; Toxicity;
Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease
Keywords: Alisertib; ARGX-110; Belinostat; Bendamustine; Brentuximab vedotin; Copanlisib; Duvelisib; Gemcitabine; Lenalidomide; Mogamulizumab; Peripheral T-cell lymphoma; Pralatrexate; Refractory; Relapsed; Romidepsin; Selinexor;
Efficacy and Safety of Bendamustine and Ibrutinib in Previously Untreated Patients With Chronic Lymphocytic Leukemia: Indirect Comparison
Keywords: Bendamustine; CLL; First line of treatment; Ibrutinib; Indirect comparison;
Bendamustine increases interleukin-10 secretion from B cells via p38 MAP kinase activation
Keywords: Bendamustine; B cells; Interleukin-10; p38 MAP kinase
Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials
Keywords: Bendamustine; Rituximab; Chronic lymphocytic leukaemia; Therapy;
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments
Keywords: CLL; Bendamustine; Rituximab; Elderly patients; First-line treatment;
Optimizing the Treatment of Patients With Multiple Myeloma and Renal Impairment
Keywords: Bendamustine; Bisphosphonates; Immunomodulatory drugs; Proteasome inhibitors; Stem cell transplantation;
Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer
Keywords: Bendamustine; Small-cell lung cancer; Relapsed; Refractory; Phase II
Bendamustine Combined with Donor Lymphocytes Infusion in Hodgkin's Lymphoma Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation
Keywords: Hodgkin's lymphoma; Bendamustine; Allogeneic stem cell transplantation; Donor lymphocyte infusion
Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a retrospective analysis
Keywords: DLBCL; Bendamustine; Rituximab; Salvage therapy;
Simultaneous determination of bendamustine and its active metabolite, gamma-hydroxy-bendamustine in human plasma and urine using HPLC-fluorescence detector: Application to a pharmacokinetic study in Chinese cancer patients
Keywords: Bendamustine; Gamma-hydroxy-bendamustine; HPLC-fluorescence detector; Pharmacokinetics; Human plasma;
Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro
Keywords: Chronic lymphocytic leukemia (CLL); Poly(ADP-ribose) polymerase (PARP); CEP-8983; Bendamustine
New drugs and targeted treatments in Hodgkin's lymphoma
Keywords: Target treatments; Hodgkin's lymphoma; Brentuximab vedotin; Deacetylase inhibitors; Bendamustine; Lenalidomide; m-TOR inhibitors;
Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group
Keywords: Chronic lymphocytic leukemia; First line treatment; Bendamustine; Guidelines
Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response
Keywords: MM; Multiple myeloma; CLL; chronic lymphocytic leukemia; HDAC; histone deacetylase; HDACi; Inhibitor of HDAC; HAT; Histone acetyltransferase; PARP; poly(ADP-ribose) polymerase; ELISA; enzyme-linked immunosorbent assay; PAGE; polyacrylamide gel electrophor
A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplantation in Multiple Myeloma
Keywords: Multiple myeloma; Bendamustine; Conditioning; Transplantation; Autologous; Melphalan
Combination of Pim Kinase Inhibitor SGI-1776 and Bendamustine in B-Cell Lymphoma
Keywords: Bendamustine; Combination strategy; Mantle cell lymphoma; Pim kinase; SGI-1776
GuÃa de consenso nacionales para el estudio y tratamiento de los pacientes con leucemia linfocÃtica crónica
Keywords: Leucemia linfocÃtica crónica; SÃndrome linfoproliferativo crónico; Clorambucilo; Fludarabina; Bendamustina; Rituximab; Chronic lymphocytic leukemia; Chronic lymphoproliferative disorder; Chlorambucil; Fludarabine; Bendamustine; Rituximab;
Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe
Keywords: Apoptosis; Bendamustine; Drug resistance; Melphalan; Mitotic catastrophe; Multiple myeloma
Development and validation of sensitive liquid chromatography/tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue
Keywords: Bendamustine; Liquid chromatography–mass spectrometry; LC–MS/MS, Brain
Pneumocystis jiroveci Pneumonia in an Atypical Host
Keywords: Bendamustine; Breast Cancer; PCP; Solid Tumor;
The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines
Keywords: Mantle cell lymphoma; Bendamustine; Cytarabine; Ara-C; Cytotoxic effect; R-BAC
Development and validation of LC–MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine
Keywords: Bendamustine; Metabolites; Alkylating agent; Stability; LC–MS/MS
Management of indolent lymphoma: Where are we now and where are we going
Keywords: Indolent lymphoma; Non-Hodgkin; Follicular; Marginal zone; Small lymphocytic; Rituximab; CD20; Cyclophosphamide; Doxorubicin; Bendamustine; Fludarabine; Lenalidomide; Bortezomib; PI3K; mTOR; Bruton's tyrosine kinase; Histone deacetylase inhibitors
Bendamustine Versus Chlorambucil for the First-Line Treatment of Chronic Lymphocytic Leukemia in England and Wales: A Cost-Utility Analysis
Keywords: bendamustine; chlorambucil; chronic lymphocytic leukemia; cost-effectiveness; cost-utility; QALY;
Economic Evaluation of Sequential Treatments for Follicular Non-Hodgkin Lymphoma
Keywords: bendamustine; cost-utility analysis; quality of life; rituximab; survival; value of information;
New agents in follicular lymphoma
Keywords: bendamustine; CAL-101; Btk inhibitor; lenalidomide; lymphoma therapy
Bivalent bendamustine and melphalan derivatives as anticancer agents
Keywords: Bendamustine; Melphalan; Dimer; Drug targeting; Breast cancerDADC, 1,12-diaminododecane; DAHEPT, 1,7-diaminoheptane; DAH, 1,6-diaminohexane; DAOCT, 1,8-diaminooctane; EPR (enhanced permeability and retention) effect, the property by which macromolecules b
Mantle cell lymphoma: The promise of new treatment options
Keywords: Mantle cell lymphoma; Non-Hodgkin's lymphoma; Rituximab; Bortezomib; Flavopiridol; Bendamustine; Temsirolimus; Lenalidomide
Role of CD20 Monoclonal Antibodies in Previously Untreated Chronic Lymphocytic Leukemia
Keywords: Alemtuzumab; Bendamustine; Chemoimmunotherapy; Chlorambucil; Cyclophosphamide; Fludarabine; Mitoxantrone; Pentostatin; Rituximab
Standards for the Treatment of Relapsed Chronic Lymphocytic Leukemia: A Case-Based Study
Keywords: AlloHSCT; Bendamustine; Flavopiridol; Fludarabine-refractory disease; Lenalidomide; Rituximab; Ofatumumab
18F Labeled benzimidazole derivatives as potential radiotracer for positron emission tomography (PET) tumor imaging
Keywords: 18F; Benzimidazole derivatives; Bendamustine; Positron emission tomography;
Chronic Lymphocytic Leukemia: New Concepts for Future Therapy
Keywords: Alemtuzumab; Bendamustine; Flavopiridol; Lenalidomide; Ofatumumab
Management of Mantle Cell Lymphoma: Key Challenges and Next Steps
Keywords: Bendamustine; HyperCVAD; Lenalidomide; MIPI; R-CHOP; Rituxumab; Temsirolimus; Transplantation
Successful Treatment of Catastrophic Antiphospholipid Antibody Syndrome (CAPS) Associated With Splenic Marginal-zone Lymphoma With Low-molecular Weight Heparin, Rituximab and Bendamustine
Keywords: Catastrophic antiphospholipid antibody syndrome; Low-molecular weight heparin; Rituximab; Bendamustine;
Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients
Keywords: Relapsed SCLC; Bendamustine; Phase II study